Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 13, 2023

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions

PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer

Interventions

DRUG

Leflunomide

Leflunomide, 20-50mg PO daily

Trial Locations (1)

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors

lead

Deborah Doroshow

OTHER